Literature DB >> 17046211

Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua.

A J Matute1, W P Brouwer, E Hak, E Delgado, E Alonso, I M Hoepelman.   

Abstract

We conducted a prevalence study to gain greater insight into the aetiology, bacterial resistance and risk factors for community-acquired pneumonia (CAP) in the region of León, Nicaragua. During the period from July 2002 to January 2005, all consecutive patients with signs and symptoms suggestive of CAP were included in the study. Sputum samples, paired serum samples and urinary samples were collected for the detection of respiratory pathogens. The most frequently identified pathogens were Streptococcus pneumoniae (17%), followed by Staphylococcus aureus (5%), Chlamydia pneumoniae (5%) and Mycoplasma pneumoniae (4%). Pseudomonas aeruginosa was cultured from 5% of patients. No pathogens were identified in 55%. All tested S. pneumoniae were sensitive to erythromycin and penicillin. In contrast, resistance of S. aureus to penicillin and erythromycin was high.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046211     DOI: 10.1016/j.ijantimicag.2006.07.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Prevalence of gram negative bacteria causing community acquired pneumonia among adults in Mwanza City, Tanzania.

Authors:  Peter Kishimbo; Nyambura Moremi Sogone; Fredrick Kalokola; Stephen E Mshana
Journal:  Pneumonia (Nathan)       Date:  2020-08-05

2.  Incidence of Hospitalized Pneumococcal Pneumonia among Adults in Guatemala, 2008-2012.

Authors:  Carmen Lucía Contreras; Jennifer R Verani; María Renee Lopez; Antonio Paredes; Chris Bernart; Fabiola Moscoso; Aleida Roldan; Wences Arvelo; Kim A Lindblade; John P McCracken
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

3.  Surveillance for hospitalized acute respiratory infection in Guatemala.

Authors:  Jennifer R Verani; John McCracken; Wences Arvelo; Alejandra Estevez; Maria Renee Lopez; Lissette Reyes; Juan Carlos Moir; Chris Bernart; Fabiola Moscoso; Jennifer Gray; Sonja J Olsen; Kim A Lindblade
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 4.  Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.

Authors:  Kay Wang; Peter Gill; Rafael Perera; Anne Thomson; David Mant; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 5.  Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.

Authors:  Maria A Said; Hope L Johnson; Bareng A S Nonyane; Maria Deloria-Knoll; Katherine L O'Brien; Felipe Andreo; Bojana Beovic; Silvia Blanco; Wim G Boersma; David R Boulware; Jay C Butler; Jordi Carratalà; Feng-Yee Chang; Patrick G P Charles; Alejandro A Diaz; Jose Domínguez; Naomi Ehara; Henrik Endeman; Vicenç Falcó; Miquel Falguera; Kiyoyasu Fukushima; Carolina Garcia-Vidal; Daniel Genne; Igor A Guchev; Felix Gutierrez; Susanne S Hernes; Andy I M Hoepelman; Ulla Hohenthal; Niclas Johansson; Vitezslav Kolek; Roman S Kozlov; Tsai-Ling Lauderdale; Ivana Mareković; Mar Masiá; Matta A Matta; Òscar Miró; David R Murdoch; Eric Nuermberger; Richard Paolini; Rafael Perelló; Dominic Snijders; Vanda Plečko; Roger Sordé; Kristoffer Strålin; Menno M van der Eerden; Angel Vila-Corcoles; James P Watt
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 6.  A Compendium for Mycoplasma pneumoniae.

Authors:  Gretchen L Parrott; Takeshi Kinjo; Jiro Fujita
Journal:  Front Microbiol       Date:  2016-04-12       Impact factor: 5.640

7.  Antimicrobial resistance in bacterial pathogens among hospitalized children with community acquired lower respiratory tract infections in Dongguan, China (2011-2016).

Authors:  Xiaoguang He; Mingyu Xie; Siping Li; Junqin Ye; Qi Peng; Qiang Ma; Xiaomei Lu; Baimao Zhong
Journal:  BMC Infect Dis       Date:  2017-09-11       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.